These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 21286012

  • 1. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
    Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.
    J Korean Med Sci; 2011 Feb; 26(2):214-21. PubMed ID: 21286012
    [Abstract] [Full Text] [Related]

  • 2. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherübl H.
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [Abstract] [Full Text] [Related]

  • 3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 4. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
    Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I.
    Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
    [Abstract] [Full Text] [Related]

  • 5. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
    Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC.
    Oncotarget; 2016 Jan 05; 7(1):473-89. PubMed ID: 26595522
    [Abstract] [Full Text] [Related]

  • 6. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
    Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT.
    Invest New Drugs; 2013 Feb 05; 31(1):30-8. PubMed ID: 22565394
    [Abstract] [Full Text] [Related]

  • 7. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.
    Lung Cancer; 2012 Dec 05; 78(3):193-200. PubMed ID: 22985911
    [Abstract] [Full Text] [Related]

  • 8. HBx mutations promote hepatoma cell migration through the Wnt/β-catenin signaling pathway.
    Chen Z, Tang J, Cai X, Huang Y, Gao Q, Liang L, Tian L, Yang Y, Zheng Y, Hu Y, Tang N.
    Cancer Sci; 2016 Oct 05; 107(10):1380-1389. PubMed ID: 27420729
    [Abstract] [Full Text] [Related]

  • 9. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
    Wu YH, Ai X, Liu FY, Liang HF, Zhang BX, Chen XP.
    Mol Med Rep; 2016 Feb 05; 13(2):1345-52. PubMed ID: 26648552
    [Abstract] [Full Text] [Related]

  • 10. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
    Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT.
    Mol Cancer Ther; 2012 Feb 05; 11(2):360-9. PubMed ID: 22144664
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
    Huang P, Zhuang B, Zhang H, Yan H, Xiao Z, Li W, Zhang J, Tang Q, Hu K, Koeffler HP, Wang J, Yin D.
    Clin Cancer Res; 2015 Oct 01; 21(19):4420-30. PubMed ID: 26059188
    [Abstract] [Full Text] [Related]

  • 12. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2005 Dec 01; 12(4):983-98. PubMed ID: 16322337
    [Abstract] [Full Text] [Related]

  • 13. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Dec 01; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 14. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 15. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 21; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 17. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
    J Cell Physiol; 2006 May 01; 207(2):420-7. PubMed ID: 16419029
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH.
    Clin Mol Hepatol; 2015 Mar 01; 21(1):49-59. PubMed ID: 25834802
    [Abstract] [Full Text] [Related]

  • 19. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT, Xiao GH.
    FEBS J; 2013 May 01; 280(9):2027-41. PubMed ID: 23461856
    [Abstract] [Full Text] [Related]

  • 20. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways.
    Wang HY, Yang SL, Liang HF, Li CH.
    Int J Mol Sci; 2014 Feb 26; 15(3):3507-18. PubMed ID: 24577313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.